MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.85
-0.05
-0.23%
Opening 15:15 11/21 EST
OPEN
21.96
PREV CLOSE
21.90
HIGH
22.43
LOW
21.82
VOLUME
329.76K
TURNOVER
--
52 WEEK HIGH
49.25
52 WEEK LOW
19.35
MARKET CAP
1.15B
P/E (TTM)
11.12
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SUPN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SUPN News

  • Investors Who Bought Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Five Years Ago Are Now Up 148%
  • Simply Wall St..2d ago
  • Supernus Pharmaceuticals seeks FDA approval for ADHD drug
  • American City Business Journals.11/12 23:14
  • Supernus to Present at Two November Healthcare Conferences
  • GlobeNewswire.11/12 21:05
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.11/12 12:20

More

Industry

Pharmaceuticals
+0.46%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Name
Price
%Change

About SUPN

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
More

Webull offers Supernus Pharmaceuticals Inc (SUPN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.